OncLive TV

Luis E. Raez, MD, discusses molecular testing, screening gaps, and global drug access challenges in lung cancer across Latin America and the US.

Alexander I. Spira, MD, PhD, FACP, FASCO, discusses phase 1 dose-optimization data supporting the 2.5 mg/kg dose of iza-bren in EGFR-mutated NSCLC.

Stephen V. Liu, MD, discusses building on durvalumab consolidation with tarlatamab and other novel agents in limited-stage SCLC.

Enriqueta Felip, MD, PhD, discusses selecting next-generation ROS1 TKIs after progression on crizotinib or entrectinib in NSCLC.

Luis Paz-Ares, MD, PhD, discusses protocols for managing T-cell engager and antibody-drug conjugate toxicities in lung cancer.

Tetsuya Mitsudomi, MD, PhD, discusses classifying and individualizing treatment for uncommon EGFR mutations in NSCLC.

Yang Xia, MD, PhD, discusses strategies for overcoming EGFR TKI resistance, including biomarker-selected and -unselected approaches.

Molly Li, MBBS, discusses selecting between HER2-directed TKIs and antibody-drug conjugates in first-line HER2-mutant NSCLC.

Grant outlines open questions in perioperative NSCLC, from neoadjuvant sequencing and adjuvant selection to whether ctDNA is ready for practice.

A hematology-oncology fellow explains how trainees can use poster walks, follow-up contact, and review articles to find mentors and generate research questions.

Prithviraj Bose, MD, discusses selinexor's existing myeloma approval and how phase 3 SENTRY data could shape its use with ruxolitinib in myelofibrosis.

Naseema Gangat, MBBS, reviews cohort-specific hematologic response rates and safety findings for selcodebart in myelofibrosis.

David Sallman, MD, discusses planned development and combination strategies for the NEK7 inhibitor ofirnoflast in lower-risk MDS.

Naseema Gangat, MBBS, discusses phase 2 efficacy and safety data for DISC-3405, an anti-TMPRSS6 monoclonal antibody, in polycythemia vera.

E. Anders Kolb, MD, breaks down a new way to measure how blood cancer treatment advances translate into years of life saved.

David B. Sykes, MD, PhD, discusses the rationale for exploring the oral CXCR4 antagonist mavorixafor in patients with chronic neutropenia.

Aaron Gerds, MD, MS, discusses how platelet count and anemia guide JAK inhibitor selection for patients with myelofibrosis.

Brandon Huffman, MD, discusses INCB161734 and how the phase 3 DAWN-303 trial is testing it in metastatic pancreatic cancer.

Hagop M. Kantarjian, MD, discusses 5-year OPTIC trial data supporting a response-based, dose-reduction strategy for ponatinib in chronic-phase CML.

Ruben Mesa, MD, FACP, discusses the FDA approval of ropeginterferon alfa-2b-njft and the unmet need it addresses in essential thrombocythemia.

Uma Borate, MBBS, discusses reducing treatment toxicity in older patients with AML and the potential for time-limited therapy strategies.

Charles E. Geyer, MD, discusses ILD and radiation pneumonitis incidence by radiotherapy timing with T-DXd in a DESTINY-Breast05 safety analysis.

Uma Borate, MBBS, MS, discusses results of the OPTI-AML trial comparing 14- and 28-day venetoclax dosing in older adults with acute myeloid leukemia.

Kim A. Reiss Binder, MD, notes the significance of the approval of daraxonrasib for metastatic PDAC and how it positions a new era for RAS-targeted drugs.

Adanma Ayanambakkam, MD, MS, discusses safety data with darlifarnib plus cabozantinib in RCC.

Daniel Morillo, MD, discusses future research directions for golcadomide in relapsed/refractory follicular lymphoma.

Zulfa Omer, MD, discusses BTK degraders, how they differentiate from BTK inhibitors, and their remaining unknowns for chronic lymphocytic leukemia.

Adanma Ayanambakkam, MD, MS, discusses the design of the phase 1a FIT-001 trial of darlifarnib plus cabozantinib in RCC.

Zev A. Wainberg, MD, discusses the mechanism of action of zanidatamab and its FDA approval as a new frontline option for HER2-positive gastric cancer.

Neeta Somaiah, MD, discusses efficacy data for bezuclastinib plus sunitinib from the Peak study in advanced gastrointestinal stromal tumors.